News
Company News: Nature Medicine reports elimination of large tumors in mice by messenger RNA-encoded bispecific antibodies
– Novel mRNA-based antibody drug class holds promise for fast development of potent immunotherapies
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel class of mRNA-encoded antibody drugs called RiboMABs®. In Nature Medicine, BioNTech presents the application of this technology for mRNA-based in vivo delivery of T cell engaging bispecific antibodies. The study entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” can be found here: http://nature.com/articles/doi:10.1038/nm.4356.
Company News: Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
– Curetis reiterates that it expects FDA to provide decision on clearance of Unyvero LRT in the second half of 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today provided an update regarding the ongoing interactive review by the U.S. Food and Drug Administration (FDA) of its 510(k) application for clearance of the Unyvero Platform and Lower Respiratory Tract Infection (LRT) Application Cartridge.
Company News: Curetis Provides Business and Financial Update for the First Quarter 2017
– First quarter 2017 revenue increases 2.6-fold year over year
– Successful completion of CE performance evaluation study and launch of Unyvero IAI Intra-Abdominal Infections (IAI) Cartridge
– Incorporation of wholly-owned subsidiary Ares Genetics to accelerate commercialization of GEAR database
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first quarter ended March 31, 2017, and provided details on its outlook for the remainder of the year.
Company News: Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
– Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA).